Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
https://www.zacks.com/stock/news/2262623/bristol-myers-bmy-q1-loss-narrower-than-expected-sales-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-2262623
Apr 25, 2024 - Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance. However, Opdivo sales disappoint.
0
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why
https://www.zacks.com/stock/news/2257012/2seventy-bio-tsvt-rises-more-than-50-in-3-months-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2257012
Apr 17, 2024 - The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.
0
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
https://www.fool.com/investing/2024/04/17/2-high-yield-dividend-stocks-to-hold-for-10-years/?source=iedfolrf0000001
Apr 17, 2024 - These income stocks look like good options at current levels.
0
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
https://www.zacks.com/stock/news/2255656/bristol-myers-squibb-bmy-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2255656
Apr 15, 2024 - Bristol Myers Squibb (BMY) closed the most recent trading day at $48.51, moving +0.48% from the previous trading session.
0
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
https://www.zacks.com/stock/news/2253877/alx-oncology-alxo-posts-upbeat-results-from-lymphoma-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253877
Apr 11, 2024 - ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.
0
Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data
https://www.zacks.com/stock/news/2252898/bristol-myers-bmy-reports-positive-colorectal-cancer-study-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2252898
Apr 09, 2024 - Bristol Myers' (BMY) Krazati, in combination with cetuximab, demonstrates clinically meaningful activity as a targeted treatment option for patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer.
0
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Abecma
https://www.zacks.com/stock/news/2252179/bristol-myers-bmy-gets-fda-nod-for-label-expansion-of-abecma?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2252179
Apr 08, 2024 - Bristol Myers (BMY) wins FDA approval for CAR T cell immunotherapy, Abecma, in earlier lines of treatment for patients with relapsed or refractory multiple myeloma.
0
Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion
https://www.zacks.com/stock/news/2249839/bristol-myers-bmy-wins-ec-nod-for-reblozyl-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249839
Apr 03, 2024 - Bristol Myers (BMY) receives European Commission's approval for a label expansion of Reblozyl (luspatercept) for another indication.
0
Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts
https://www.zacks.com/stock/news/2246994/bristol-myers-squibb-bmy-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2246994
Mar 27, 2024 - In the most recent trading session, Bristol Myers Squibb (BMY) closed at $53.25, indicating a +1.33% shift from the previous trading day.
0
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
https://www.zacks.com/stock/news/2244465/bristol-myers-squibb-bmy-stock-declines-while-market-improves-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2244465
Mar 21, 2024 - In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.59, marking a -0.56% move from the previous day.
0